Notícias e Atividades da Tonix Pharmaceuticals

Tonix Pharmaceuticals é uma empresa listada sob o símbolo TNXP (US).

Veja o organograma con seus 21 executivos principais

Biografias mais buscadas da Tonix Pharmaceuticals

• Seth Lederman, Co-Founder, Chairman and Chief Executive Officer
• Adeoye Olukotun, Director
• Carolyn Taylor, Director

Recentes movimentos de executivos em Tonix Pharmaceuticals

• Siobhan Fogarty antes Executive Vice President, Product Development, foi promovido a Chief Technical Officer  (Notícia publicada em 5 de fevereiro de 2025).
• Gary Ainsworth, ingressou na Companhia como Vice President of Market Access  (Notícia publicada em 10 de janeiro de 2025).
• Bradley Raudabaugh, ingressou na Companhia como Vice President, Marketing  (Notícia publicada em 3 de dezembro de 2024).

Clique aqui para ver outras movimentos em Tonix Pharmaceuticals

Criar um alerta
para seguir os movimentos de executivos da Tonix Pharmaceuticals.

Tonix Pharmaceuticals possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Tonix Pharmaceuticals

• Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
• Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
• Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
• Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
• Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
• Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
• Press Releases
• Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate
• Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
• Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
• View more press releases Close

Redes sociais sobre Tonix Pharmaceuticals

• Tonix Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Tonix Pharmaceuticals na LinkedIn, Twitter e YouTube